Diagnostic Radiopharmaceuticals Contrast Media Market: Market Size & Forecast 2026

The market covers products that enhance the visibility of internal bodily structures during diagnostic imaging procedures. Contrast media includes iodine-based, gadolinium-based, and barium-based agents used primarily in X-ray, CT, and MRI, while radiopharmaceuticals are radioactive compounds used in nuclear medicine, particularly PET and SPECT scans. The combined global market stands at approximately USD 10.0 billion in 2025, with industry-derived projections suggesting growth to around USD 13.90 billion by 2030 at a compound annual growth rate near 6.8%. These figures reflect commercial research estimates, as no government statistical agency publishes an official market size for this specific combined category.

• •No official government or statistical agency publishes a direct global market valuation for the combined diagnostic radiopharmaceuticals and contrast media market
• •Market size estimates vary across research firms, with the contrast media standalone segment alone estimated between USD 5.1 billion and USD 7.3 billion in 2025
• •The broader nuclear medicine market was estimated separately at USD 10.41 billion in 2025, growing at approximately 15.1% CAGR, reflecting strong momentum in radiopharmaceutical innovation

The aging global population is a primary driver, as older adults require more diagnostic imaging for age-related conditions including cancer, cardiovascular disease, and neurological disorders. Rising prevalence of chronic diseases, particularly cancer and heart disease, is increasing the volume of imaging procedures worldwide. Expanding healthcare infrastructure and diagnostic imaging access in emerging markets, alongside technological advancements such as hybrid imaging modalities and next-generation contrast agents, are further propelling market growth.

• •Aging demographics and rising chronic disease prevalence are increasing the global volume of CT, MRI, PET, and SPECT imaging procedures
• •Technological innovations, including theranostic radiopharmaceuticals and advanced MRI contrast agents, are creating new clinical applications and driving adoption
• •Expanding diagnostic imaging access in Asia-Pacific, Latin America, and the Middle East is opening new market opportunities

The market is broadly divided into contrast media and radiopharmaceuticals. Contrast media includes iodine-based agents for X-ray and CT, gadolinium-based agents for MRI, and barium sulfate suspensions, while radiopharmaceuticals span PET tracers such as FDG and PSMA ligands, as well as SPECT agents. The contrast media segment alone is valued between USD 5.1 billion and USD 7.3 billion in 2025, while radiopharmaceuticals represent a smaller but faster-growing share. North America and Europe dominate current market share, with North America leading due to high healthcare spending, advanced imaging infrastructure, and early adoption of new radiopharmaceutical therapies.

• •North America holds the largest market share, supported by advanced healthcare infrastructure, high imaging procedure volumes, and favorable reimbursement environments
• •Asia-Pacific is the fastest-growing regional market, driven by rising healthcare spending, growing middle-class populations, and expanding diagnostic imaging networks
• •The radiopharmaceuticals segment is growing faster than contrast media, with some estimates projecting over 10% CAGR compared to roughly 3-8% for contrast media depending on the segment

What are the recent trends and outlook?

The theranostics paradigm, combining diagnostic imaging with targeted radionuclide therapy, is accelerating investment and pipeline development in the radiopharmaceuticals segment. Theranostics uses the same molecule labeled with different isotopes for both imaging and treatment, and this approach is generating strong clinical and commercial momentum, particularly in oncology. Meanwhile, AI-powered image analysis and workflow automation are beginning to influence how contrast media dosing and radiopharmaceutical scheduling are managed in clinical practice. Looking ahead, the market is expected to maintain steady growth through 2030, with the radiopharmaceuticals segment outpacing contrast media as new molecular imaging agents and theranostic products advance through clinical development.

• •Theranostic radiopharmaceuticals are a major emerging trend, with growing clinical adoption of targeted radionuclide therapies for cancers including prostate and neuroendocrine tumors
• •AI and digital imaging integration are improving contrast agent dosing precision and radiopharmaceutical supply chain management
• •The market is expected to reach approximately USD 13.90 billion by 2030, with radiopharmaceuticals projected to grow at a faster rate than the contrast media segment